Catena Biosciences vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC W21 protein conjugation technology for homogeneous ADCs and biologics at $9.1M total ($2.35M seed May 2024 LongeVC/Caffeinated) and $750K revenue Jun 2025; MPC platform competing with Ajinomoto and Abzena for precise ADC conjugation services.
About
Catena Biosciences is a United States-based biotechnology company — backed by Y Combinator (W21) with $9.1 million in total funding including a $2.35 million seed round in May 2024 from LongeVC, CA Innovation Fund, Civilization Ventures, Pioneer Fund, Freeflow Ventures, Caffeinated Capital, and BrightEdge Capital, plus NIH SBIR grants — developing next-generation protein conjugation technology that enables the rapid, selective attachment of functional payloads (drugs, labels, polymers, other proteins) to therapeutic proteins using natural amino acids as conjugation handles, generating $750,000 in annual revenue as of June 2025 and serving pharmaceutical companies and researchers developing antibody-drug conjugates (ADCs), bispecific antibodies, vaccine adjuvants, and next-generation protein therapeutics for autoimmune disorders, oncology, and infectious disease.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Catena Biosciences vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.